Current understanding of methamphetamine-associated dopaminergic neurodegeneration and psychotoxic behaviors

Eun Joo Shin, Duy Khanh Dang, The Vinh Tran, Hai Quyen Tran, Ji Hoon Jeong, Seung Yeol Nah, Choon Gon Jang, Kiyofumi Yamada, Toshitaka Nabeshima, Hyoung Chun Kim

Research output: Contribution to journalReview article

22 Citations (Scopus)

Abstract

Clinical and preclinical studies have indicated that chronic methamphetamine (MA) use is associated with extensive neurodegeneration, psychosis, and cognitive impairment. Evidence from animal models has suggested a considerable role of excess dopamine or glutamate, oxidative stress, neuroinflammation, and apoptosis in MA-induced neurotoxicity, and that protein kinase Cδ might mediate the interaction among these factors. In addition, the relatively long-lasting and recurrent nature of MA psychosis has been reproduced in animals treated with various dosing regimens of MA, which have shown behavioral sensitization, sociability deficits, and impaired prepulse inhibition. Genetic predisposition as well as dopaminergic and glutamatergic alterations might be important in the development of MA psychosis. Neuroimaging studies have identified functional and morphological changes related to the cognitive dysfunction shown in chronic MA users. Failure in the task-evoked phosphorylation of extracellular signal-related kinase likely underlies MA-induced memory impairment. Recent progress has suggested certain roles of oxidative stress and neuroinflammation in the psychosis and cognitive deficits induced by repeated low doses of MA. This review provides a comprehensive description of pertinent findings from human and animal studies, with an emphasis on the current understanding of the underlying mechanisms of MA neuropsychotoxicity and its relevance to Parkinson’s disease or schizophrenia.

Original languageEnglish
Pages (from-to)403-428
Number of pages26
JournalArchives of Pharmacal Research
Volume40
Issue number4
DOIs
Publication statusPublished - 01-04-2017

Fingerprint

Methamphetamine
Psychotic Disorders
Animals
Oxidative stress
Oxidative Stress
Neuroimaging
Phosphorylation
Genetic Predisposition to Disease
Protein Kinase C
Parkinson Disease
Glutamic Acid
Dopamine
Schizophrenia
Phosphotransferases
Animal Models
Apoptosis
Data storage equipment

All Science Journal Classification (ASJC) codes

  • Molecular Medicine
  • Drug Discovery
  • Organic Chemistry

Cite this

Shin, E. J., Dang, D. K., Tran, T. V., Tran, H. Q., Jeong, J. H., Nah, S. Y., ... Kim, H. C. (2017). Current understanding of methamphetamine-associated dopaminergic neurodegeneration and psychotoxic behaviors. Archives of Pharmacal Research, 40(4), 403-428. https://doi.org/10.1007/s12272-017-0897-y
Shin, Eun Joo ; Dang, Duy Khanh ; Tran, The Vinh ; Tran, Hai Quyen ; Jeong, Ji Hoon ; Nah, Seung Yeol ; Jang, Choon Gon ; Yamada, Kiyofumi ; Nabeshima, Toshitaka ; Kim, Hyoung Chun. / Current understanding of methamphetamine-associated dopaminergic neurodegeneration and psychotoxic behaviors. In: Archives of Pharmacal Research. 2017 ; Vol. 40, No. 4. pp. 403-428.
@article{8385a3ccc3bb46cc95f2008e9261dae7,
title = "Current understanding of methamphetamine-associated dopaminergic neurodegeneration and psychotoxic behaviors",
abstract = "Clinical and preclinical studies have indicated that chronic methamphetamine (MA) use is associated with extensive neurodegeneration, psychosis, and cognitive impairment. Evidence from animal models has suggested a considerable role of excess dopamine or glutamate, oxidative stress, neuroinflammation, and apoptosis in MA-induced neurotoxicity, and that protein kinase Cδ might mediate the interaction among these factors. In addition, the relatively long-lasting and recurrent nature of MA psychosis has been reproduced in animals treated with various dosing regimens of MA, which have shown behavioral sensitization, sociability deficits, and impaired prepulse inhibition. Genetic predisposition as well as dopaminergic and glutamatergic alterations might be important in the development of MA psychosis. Neuroimaging studies have identified functional and morphological changes related to the cognitive dysfunction shown in chronic MA users. Failure in the task-evoked phosphorylation of extracellular signal-related kinase likely underlies MA-induced memory impairment. Recent progress has suggested certain roles of oxidative stress and neuroinflammation in the psychosis and cognitive deficits induced by repeated low doses of MA. This review provides a comprehensive description of pertinent findings from human and animal studies, with an emphasis on the current understanding of the underlying mechanisms of MA neuropsychotoxicity and its relevance to Parkinson’s disease or schizophrenia.",
author = "Shin, {Eun Joo} and Dang, {Duy Khanh} and Tran, {The Vinh} and Tran, {Hai Quyen} and Jeong, {Ji Hoon} and Nah, {Seung Yeol} and Jang, {Choon Gon} and Kiyofumi Yamada and Toshitaka Nabeshima and Kim, {Hyoung Chun}",
year = "2017",
month = "4",
day = "1",
doi = "10.1007/s12272-017-0897-y",
language = "English",
volume = "40",
pages = "403--428",
journal = "Archives of Pharmacal Research",
issn = "0253-6269",
publisher = "Pharmaceutical Society of Korea",
number = "4",

}

Shin, EJ, Dang, DK, Tran, TV, Tran, HQ, Jeong, JH, Nah, SY, Jang, CG, Yamada, K, Nabeshima, T & Kim, HC 2017, 'Current understanding of methamphetamine-associated dopaminergic neurodegeneration and psychotoxic behaviors', Archives of Pharmacal Research, vol. 40, no. 4, pp. 403-428. https://doi.org/10.1007/s12272-017-0897-y

Current understanding of methamphetamine-associated dopaminergic neurodegeneration and psychotoxic behaviors. / Shin, Eun Joo; Dang, Duy Khanh; Tran, The Vinh; Tran, Hai Quyen; Jeong, Ji Hoon; Nah, Seung Yeol; Jang, Choon Gon; Yamada, Kiyofumi; Nabeshima, Toshitaka; Kim, Hyoung Chun.

In: Archives of Pharmacal Research, Vol. 40, No. 4, 01.04.2017, p. 403-428.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Current understanding of methamphetamine-associated dopaminergic neurodegeneration and psychotoxic behaviors

AU - Shin, Eun Joo

AU - Dang, Duy Khanh

AU - Tran, The Vinh

AU - Tran, Hai Quyen

AU - Jeong, Ji Hoon

AU - Nah, Seung Yeol

AU - Jang, Choon Gon

AU - Yamada, Kiyofumi

AU - Nabeshima, Toshitaka

AU - Kim, Hyoung Chun

PY - 2017/4/1

Y1 - 2017/4/1

N2 - Clinical and preclinical studies have indicated that chronic methamphetamine (MA) use is associated with extensive neurodegeneration, psychosis, and cognitive impairment. Evidence from animal models has suggested a considerable role of excess dopamine or glutamate, oxidative stress, neuroinflammation, and apoptosis in MA-induced neurotoxicity, and that protein kinase Cδ might mediate the interaction among these factors. In addition, the relatively long-lasting and recurrent nature of MA psychosis has been reproduced in animals treated with various dosing regimens of MA, which have shown behavioral sensitization, sociability deficits, and impaired prepulse inhibition. Genetic predisposition as well as dopaminergic and glutamatergic alterations might be important in the development of MA psychosis. Neuroimaging studies have identified functional and morphological changes related to the cognitive dysfunction shown in chronic MA users. Failure in the task-evoked phosphorylation of extracellular signal-related kinase likely underlies MA-induced memory impairment. Recent progress has suggested certain roles of oxidative stress and neuroinflammation in the psychosis and cognitive deficits induced by repeated low doses of MA. This review provides a comprehensive description of pertinent findings from human and animal studies, with an emphasis on the current understanding of the underlying mechanisms of MA neuropsychotoxicity and its relevance to Parkinson’s disease or schizophrenia.

AB - Clinical and preclinical studies have indicated that chronic methamphetamine (MA) use is associated with extensive neurodegeneration, psychosis, and cognitive impairment. Evidence from animal models has suggested a considerable role of excess dopamine or glutamate, oxidative stress, neuroinflammation, and apoptosis in MA-induced neurotoxicity, and that protein kinase Cδ might mediate the interaction among these factors. In addition, the relatively long-lasting and recurrent nature of MA psychosis has been reproduced in animals treated with various dosing regimens of MA, which have shown behavioral sensitization, sociability deficits, and impaired prepulse inhibition. Genetic predisposition as well as dopaminergic and glutamatergic alterations might be important in the development of MA psychosis. Neuroimaging studies have identified functional and morphological changes related to the cognitive dysfunction shown in chronic MA users. Failure in the task-evoked phosphorylation of extracellular signal-related kinase likely underlies MA-induced memory impairment. Recent progress has suggested certain roles of oxidative stress and neuroinflammation in the psychosis and cognitive deficits induced by repeated low doses of MA. This review provides a comprehensive description of pertinent findings from human and animal studies, with an emphasis on the current understanding of the underlying mechanisms of MA neuropsychotoxicity and its relevance to Parkinson’s disease or schizophrenia.

UR - http://www.scopus.com/inward/record.url?scp=85014015071&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85014015071&partnerID=8YFLogxK

U2 - 10.1007/s12272-017-0897-y

DO - 10.1007/s12272-017-0897-y

M3 - Review article

C2 - 28243833

AN - SCOPUS:85014015071

VL - 40

SP - 403

EP - 428

JO - Archives of Pharmacal Research

JF - Archives of Pharmacal Research

SN - 0253-6269

IS - 4

ER -